Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Alzheimer's disease proteome-wide association study implicates adaptive immunity and identifies risk genes LILRB1 and SIRPA.

Science translational medicine·2026
Same author

Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to action.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Concordance between domain-based neuropsychological profiles and clinical phenotypes in young-onset dementia.

The Clinical neuropsychologist·2026
Same author

Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial.

Nature medicine·2026
Same author

Plasma p-tau markers, vascular factors, and cognitive decline in the CIMA-Q cohort.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Tau-PET and CSF MTBR-tau243 comparisons validate increased tau aggregation in females.

European journal of nuclear medicine and molecular imaging·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Alexa Pichet Binette1,2,3, Ruben Smith4,5, Gemma Salvadó1,6

  • 1Clinical Memory Research Unit, Lund University, Lund, Sweden.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

使用tau-PET的新阿尔茨海默病 (AD) 标准表明,共同病理显著影响症状严重程度. 了解这些差异是准确的AD诊断和预后的关键.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 生物标志物研究 生物标志物研究
  • 神经退行性疾病 神经退行性疾病

背景情况:

  • 最新的阿尔茨海默病 (AD) 标准将tau-PET成像作为核心生物标志物.
  • 病理的空间范围现在是阿尔茨海默病的修订生物分期的一部分.
  • 这项研究旨在在大型队列中实施和验证这些新标准.

研究的目的:

  • 实施更新的阿尔茨海默病 (AD) 阶段化标准,将tau-PET纳入大型研究队列.
  • 为了比较具有一致的生物和临床阶段的个体与具有不同阶段的个体.
  • 调查AD阶段不匹配的个体中共同病理和人口统计学的作用.

主要方法:

  • 分析了BioFINDER-2队列中的838名粉样β阳性参与者与tau-PET ([18F]RO948) 的数据.
  • 参与者根据临床阶段 (认知正常到痴呆) 和生物阶段 (早期到高级) 进行分类.
  • 人口统计,神经退行标志物 (皮层厚度,TDP-43MRI签名,NfL),α-synuclein,GFAP和脑血管病变在一致和不一致的分期组之间进行了比较.

主要成果:

  • 51.3%的参与者表现出比生物阶段 (临床>生物) 更先进的临床损伤.
  • 临床 > 生物组年龄较大,有更多的男性,更高的α-synuclein,高的NfL,更大的TDP-43缩,以及更多的小血管疾病.
  • 比临床更先进的生物阶段 (生物 > 临床) 个体的神经退行变化较少 (皮质较厚).

结论:

  • 这项研究验证了新的AD分期标准,强调了共同病理在症状严重性中的作用.
  • 与临床阶段预期相比,tau病理较少的个体往往表现出显著的共同病理.
  • 测量非AD生物标志物对于具有与其生物AD阶段不成比例的认知障碍患者至关重要,影响诊断和预后.